Publication | Closed Access

Oral administration of inflammatory microenvironment-responsive carrier-free infliximab nanocomplex for the targeted treatment of inflammatory bowel disease

InflammationNanomedicineCell-based Drug DeliveryAnti-inflammatoryEngineeringTargeted TreatmentMedicineImmunologyOral AdministrationBiomedical EngineeringUlcerative ColitisImmunotherapyPharmacology